Alvotech streymir kynningu fyrir fjárfesta 3. apríl 2024 kl. 12:15 að íslenskum tíma
April 03, 2024 06:43 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið myndi streyma stuttri kynningu fyrir fjárfesta kl. 12:15 að íslenskum tíma í dag, 3. apríl 2024. Anil Okay, framkvæmdastjóri viðskipta mun þar...
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
April 03, 2024 06:43 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a...
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
March 22, 2024 04:00 ET
|
Molecure
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the...
Alvotech heldur uppgjörsfund fyrir árið 2023 í beinu streymi þann 21. mars nk. kl. 12:00 að íslenskum tíma
March 05, 2024 16:01 ET
|
Alvotech
Fjárfestadagur, sem einnig verður sendur út á vefnum, verður haldinn föstudaginn 22. mars nk. Alvotech (NASDAQ: ALVO) birtir ársuppgjör fyrir 2023 að kvöldi miðvikudagsins 20. mars nk., eftir lokun...
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
March 05, 2024 16:01 ET
|
Alvotech
Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar...
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
March 04, 2024 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech Appoints Interim Chief Quality Officer
February 29, 2024 16:05 ET
|
Alvotech
REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Cybrexa Regains Rights to CBX-12
February 06, 2024 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024 04:00 ET
|
Alvotech
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints Prolia® and Xgeva® (denosumab) are indicated...
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
January 19, 2024 11:30 ET
|
Alvotech
REYKJAVIK, Iceland, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...